A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

NCT04220307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL: AK104

Sponsor

Akeso

Collaborators

[object Object]